## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.8% below STRENGTH zone (3.0-6.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($140.08)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Agilent Technologies price driven lower by pivotal resistance - Forecast today - 02-12-2025**
- Source: Economies.com | 20251202T132500 | Somewhat-Bullish | Relevance: 100%
- Agilent Technologies (A) declined after hitting a pivotal resistance level at $153.75, prompting profit-taking despite an overall short-term ascending trend. The stock is attempting to relieve overbought RSI saturation and consolidate positive momentum. A breakout above $153.75 is needed to target the next resistance at $169.50, with a bullish forecast.

**2. Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight**
- Source: BioSpace | 20251202T103950 | Bullish | Relevance: 100%
- Agilent Technologies announced new 21 CFR Part 11 compliance software for its xCELLigence Real-Time Cell Analysis (RTCA) eSight system. This upgrade extends the system's usability from drug discovery to GMP-regulated manufacturing and quality control settings by adding security features like user authentication, electronic signatures, and audit trails. The software addresses the growing need for regulatory-ready digital lab tools in biopharma and cell therapy manufacturing, ensuring data integrity and streamlining regulatory submissions.

**3. Jim Cramer on Agilent: "The Thing's Just Caught Fire"**
- Source: Finviz | 20251204T120500 | Bullish | Relevance: 100%
- Jim Cramer highlighted Agilent Technologies (NYSE: A) as a stock that has "caught fire," despite a period of choppiness for the life sciences industry post-pandemic. He noted the company's 55% surge from April lows, a solid quarter with 7% organic growth, and encouraging signs of a business turnaround driven by reshoring in life sciences manufacturing and novel medicine requirements. Cramer also mentioned that the Trump FDA under RFK Jr. has been less disruptive than expected on Wall Street.

**4. How Is Agilent Technologies' Stock Performance Compared to Other Healthcare Stocks?**
- Source: Markets Financial Content | 20251204T065000 | Somewhat-Bullish | Relevance: 100%
- Agilent Technologies (A) has shown mixed stock performance, outperforming The Health Care Select Sector SPDR Fund (XLV) over the past three months and 52 weeks but lagging XLV year-to-date. Despite strong Q4 2025 results and a positive fiscal 2026 outlook, its stock performance trails industry peer Eli Lilly and Company (LLY). Analysts hold a "Moderate Buy" rating with a price target suggesting a 13.6% upside.

**5. Dir Dolsten Sells 2,600 ($389.5K) Of Agilent Technologies Inc [A]**
- Source: TradingView | 20251203T214039 | Somewhat-Bearish | Relevance: 100%
- A Director at Agilent Technologies Inc, Mikael Dolsten, sold 2,600 shares of the company's stock on December 1, 2025. The transaction was valued at $389,511, with shares sold at a price of $149.81 each. Following this sale, Dolsten's direct holdings in Agilent Technologies Inc stand at 4,973 shares.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |
| 2025-11-25 | Wells Fargo | $175 | $150 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |
| 2025-11-25 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 22.6x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.2B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 22.6 |
| Current P/E | 24.9 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.0% to -3.8% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). MACD histogram bearish (-0.51), momentum weakening. RSI neutral at 52. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.81% (CS: 12) | Weak |
| RSI_14 | 51.5 | Neutral |
| MACD Histogram | -0.51 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.032x | Above |
| vs SMA200 | 1.197x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $148.32
- **Stop Loss:** $140.08 (5.6% risk)
- **Target:** $156.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 60
- **Position Value:** $8,899.20
- **Portfolio %:** 8.90%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*